Payment overview · 2025
General Payments
$600.88
36 reported records · 7 companies
Healthcare provider profile · identity verified
Kirtida N Ringwala, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OSHKOSH, WI · NPI 1356376966
Verified facts
What the public records show
CMS Open Payments records show Kirtida N Ringwala, MD received $600.88 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $243.00 | 40.4% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.04 | 16.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.64 | 15.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.82 | 10.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.96 | 8.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.39 | 6.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.03 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $600.88 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $101.37 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $98.04 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.42 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.55 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.24 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.82 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.96 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.29 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $43.85 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.39 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.10 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Simvastatin | Simvastatin | 355 | 100 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 281 | 50 |
| Lisinopril | Lisinopril | 267 | 80 |
| Omeprazole | Omeprazole | 264 | 76 |
| Losartan Potassium | Losartan Potassium | 225 | 63 |
| Metformin Hcl | Metformin Hcl | 213 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 42 |
| Gabapentin | Gabapentin | 176 | 43 |
| Alprazolam | Alprazolam | 151 | 33 |
| Furosemide | Furosemide | 150 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 148 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 144 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 36 |
| Allopurinol | Allopurinol | 108 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 107 | 33 |
| Potassium Chloride | Potassium Chloride | 106 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 20 |
| Finasteride | Finasteride | 99 | 24 |
| Eliquis | Apixaban | 78 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 20 |
| Trazodone Hcl | Trazodone Hcl | 71 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 20 |
| Azithromycin | Azithromycin | 68 | 49 |
| Tramadol Hcl | Tramadol Hcl | 66 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 16 |
| Gemfibrozil | Gemfibrozil | 53 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 19 |
| Carvedilol | Carvedilol | 44 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 17 |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 12 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 11 |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 32 | 12 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 15 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 21 |
| Topiramate | Topiramate | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 18 |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Prednisone | Prednisone | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Cephalexin | Cephalexin | 20 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $600.88 · 36 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error